These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 23157236)

  • 1. Current trends in epigenetic drug discovery.
    Stolfa DA; Einsle O; Sippl W; Jung M
    Future Med Chem; 2012 Oct; 4(16):2029-37. PubMed ID: 23157236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the discovery of small-molecule modulators for epigenetic processes.
    Lu Q; Quinn AM; Patel MP; Semus SF; Graves AP; Bandyopadhyay D; Pope AJ; Thrall SH
    J Biomol Screen; 2012 Jun; 17(5):555-71. PubMed ID: 22392809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the epigenetic drug discovery landscape.
    Prachayasittikul V; Prathipati P; Pratiwi R; Phanus-Umporn C; Malik AA; Schaduangrat N; Seenprachawong K; Wongchitrat P; Supokawej A; Prachayasittikul V; Wikberg JE; Nantasenamat C
    Expert Opin Drug Discov; 2017 Apr; 12(4):345-362. PubMed ID: 28276705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The zebrafish: a powerful platform for in vivo, HTS drug discovery.
    Delvecchio C; Tiefenbach J; Krause HM
    Assay Drug Dev Technol; 2011 Aug; 9(4):354-61. PubMed ID: 21309713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Project ranks billions of drug interactions.
    Reardon S
    Nature; 2013 Nov; 503(7477):449-50. PubMed ID: 24284710
    [No Abstract]   [Full Text] [Related]  

  • 7. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
    Campbell JB
    IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
    Raynal NJ; Da Costa EM; Lee JT; Gharibyan V; Ahmed S; Zhang H; Sato T; Malouf GG; Issa JJ
    Mol Cancer Ther; 2017 Feb; 16(2):397-407. PubMed ID: 27980103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetics: new possibilities for drug discovery.
    Lundstrom K
    Future Med Chem; 2017 Apr; 9(5):437-441. PubMed ID: 28362126
    [No Abstract]   [Full Text] [Related]  

  • 11. The application of next-generation sequencing technologies to drug discovery and development.
    Woollard PM; Mehta NA; Vamathevan JJ; Van Horn S; Bonde BK; Dow DJ
    Drug Discov Today; 2011 Jun; 16(11-12):512-9. PubMed ID: 21440664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer.
    Verma SK
    Methods Mol Biol; 2015; 1238():677-88. PubMed ID: 25421686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural products as catalysts for innovation: a pharmaceutical industry perspective.
    Schmitt EK; Moore CM; Krastel P; Petersen F
    Curr Opin Chem Biol; 2011 Aug; 15(4):497-504. PubMed ID: 21684800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational tools for polypharmacology and repurposing.
    Achenbach J; Tiikkainen P; Franke L; Proschak E
    Future Med Chem; 2011 Jun; 3(8):961-8. PubMed ID: 21707399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
    Cacabelos R
    Drug Dev Res; 2014 Sep; 75(6):348-65. PubMed ID: 25195579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.
    Eglen RM; Reisine T
    J Biomol Screen; 2011 Dec; 16(10):1137-52. PubMed ID: 22002420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico pharmacology for a multidisciplinary drug discovery process.
    Ortega SS; Cara LC; Salvador MK
    Drug Metabol Drug Interact; 2012; 27(4):199-207. PubMed ID: 23152402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches for high-throughput pharmacokinetic screening of low-molecular-weight drug candidates.
    Fontana S
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):139-42. PubMed ID: 24329157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common non-epigenetic drugs as epigenetic modulators.
    Lötsch J; Schneider G; Reker D; Parnham MJ; Schneider P; Geisslinger G; Doehring A
    Trends Mol Med; 2013 Dec; 19(12):742-53. PubMed ID: 24054876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Label-free screening assays: a strategy for finding better drug candidates.
    Lunn CA
    Future Med Chem; 2010 Nov; 2(11):1703-16. PubMed ID: 21428840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.